Viridans streptococci bacteraemia

Publication: 18/11/2014  --
Last review: 23/03/2020  
Next review: 23/03/2023  
Clinical Guideline
CURRENT 
ID: 4026 
Approved By: Trust Clinical Guidelines Group 
Copyright© Leeds Teaching Hospitals NHS Trust 2020  

 

This Clinical Guideline is intended for use by healthcare professionals within Leeds unless otherwise stated.
For healthcare professionals in other trusts, please ensure that you consult relevant local and national guidance.

Department of Microbiology Bacteraemia Guideline

Viridans Streptococci

Quick reference guide to the management of Viridans Streptococci
bacteraemia

This document provides guidelines for doctors on the management of patients with confirmed bacteraemias (blood cultures). This document is supplementary to, and should be used in conjunction with, the antimicrobial guidelines.

Viridans Streptococci

Back to top

Aim

The aim of this guideline is to:

  • Provide education to junior microbiology registrars
  • Support communication of blood culture results from microbiologists to ward doctors
  • Support ward doctors in treating and investigating bacteraemic patients

Back to top

Background

The blood culture process: Timings of culture, identification, susceptibility tests and clinical liaison.
How to use this guideline: This guideline should be used to help in the management of patients with a confirmed bacteraemia. The guideline should be used to support interaction with specialist advice e.g. Microbiology.

Back to top

About Viridans Streptococci

  • Viridans Streptococci are gram-positive cocci which appear as spherical or ovoid cells that form chains or pairs. The term viridans derives from the Latin word viridis, meaning green ,as they may cause green discoloration on blood agar ( a-haemolysis)
  • Clinically significant species of viridans streptococci can be assigned to one of the following groups: the mitis group, the mutans group, the salivarius group and the sanguinis group. Streptococcus anginosus (includingS. milleri) group is also classified among the Viridans Streptococci (see separate guideline)
  • Viridans Streptococci are found as part of the normal bacteria colonising the upper respiratory tract, female genital tract and gastrointestinal tract but are most prevalent in the oral cavity.
  • Viridans streptococci are considered to be bacteria of low virulence
  • Only 21% of positive blood cultures with Viridans Streptococci are thought to be significant. The remainder have been attributed to contamination3. Bacteraemia -without endocarditis-has been recognised as a problem in patients undergoing cancer chemotherapy4 and in patients with end-stage liver disease5

Back to top

Antimicrobial susceptibilities

  • Viridans Streptococci are susceptible to most antimicrobial agents, including β-lactams, macrolides, tetracyclines, quinolones and aminoglycosides. Generally community acquired isolates tend to be highly susceptible6 and resistance occurs more frequently in nosocomial infections or immunocompromised patients7,8
  • Vancomycin, linezolid, daptomycin and tigecycline have good antimicrobial activity against Streptococci.

Back to top

Clinical differential diagnosis

The differential diagnosis of bacteraemia with Viridans Streptococci includes:

  • Endocarditis
  • Central venous catheter infections
  • Aspiration pneumonia
  • Spontaneous Bacterial Peritonitis (SBP)
  • Other infections caused rarely (meningitis, otitis media, sinusitis, dental infections)

Back to top

Antimicrobial treatment

  • Antibiotic therapy should always be reviewed with results of sensitivity tests.
  • Viridans Streptococcal bacteraemias should normally be discussed with an infection specialist e.g. microbiologist.

History of the following are important to determine appropriate antimicrobial therapy

  • Source of infection
  • Allergy status

The table below outlines some of the common infections associated with each of the clinical syndromes.

Clinical diagnosis

 

Antimicrobial therapy
Note: Viridans Streptococcal bacteraemias should normally be discussed with an infection specialist e.g. microbiologist.

Endocarditis

See guideline

Aspiration Pneumonia

See guideline

Central venous access infections

See guideline

Spontaneous Bacterial Peritonitis

See guideline

Back to top

Supplementary Investigations

Consider further investigations as appropriate to source of infection, please see relevant guidelines.

Provenance

Record: 4026
Objective:
Clinical condition:
Target patient group:
Target professional group(s): Secondary Care Doctors
Pharmacists
Adapted from:

Evidence base

  • BNF
  • EMC
  • Swenson FJ etal. Clinical significance of viridans streptococci isolated from blood cultures. J Clin Microbiol 1982;15:725-727
  • Engelhard D et al. Cytoside arabinoside as a major risk factor for Streptococcus viridans septicaemia following bone marrow transplantation. A 5-year prospective study. Marrow Tranplant 1995 ;16:565-70
  • Bert F et al. Viridans group streptococci causing spontaneous bacterial peritonitis and bacteraemia in patients with end-stage lever disease. Liver Transplant. 2008;14:710-711
  • Francioli PB. Ceftriaxone and outpatient treatment for infective endocarditis.Inf Dis Clin North A, 1993;7:97-115
  • Pfaller MA et al. nosocomial streptococcal bloodstream infections in the SCOPE program:Species occurrence and antimicrobial susceptibility. Diagn Microbiol Infect Dis .1997;29:259-63
  • Trends in Antimicrobial Resistance in England and Wales 2004-2005. HPA

Approved By

Trust Clinical Guidelines Group

Document history

LHP version 1.0

Related information

Not supplied

Equity and Diversity

The Leeds Teaching Hospitals NHS Trust is committed to ensuring that the way that we provide services and the way we recruit and treat staff reflects individual needs, promotes equality and does not discriminate unfairly against any particular individual or group.